Фармакоэкономическая эффективность некоторых современных методов терапии у детей с муковисцидозом

IN THE LAST YEARS INTEREST HAS BEEN AROUSED TO PHARMACOECONOM-ICS THE ECONOMIC EVALUATION OF TREATMENT EFFECTIVENESS. THE INVESTIGATION OBJECTIVE WAS THE STUDY OF CLINICAL EFFECTIVENESS AND THE COST EXPEDIENCY OF THE INCLUSION OF SOME MODERN DRUGS AND MEDICAL TECHNOLOGIES IN THE COMPLEX THERAPY OF CYSTIC FIBROSIS (CF) IN CHILDREN FOR THE LAST DECADE IN MOSCOW. 105 PATIENTS DURING THE PERIOD FROM 1993 TO 2004 WERE INVESTIGATED. WITHIN THIS SPAN OF TIME SOME DRUGS WERE INCLUDED: SUBSTITUTIVE MICROS-PHERIC PANCREATIC ENZYMES (KREON) 1993, MUCOLYTIC AGENT DOR-NASE ALFA (PULMOZYME) AND ANTIBIOTIC CEFTAZIDIME 1998, ANTIBIOTICS CEFEPIME AND MEROPENEM 2003. SINCE 1998 PATIENTS BEGAN TO RECEIVE PLANNED DOMICILIARY INTRAVENOUS THERAPY BY ANTIBIOTICS. THE INTRODUCTION OF NEW DRUGS AND MEDICAL TECHNICS (INTRAVENOUS ANTIBACTERIAL THERAPY AT HOME) CAUSED INCREASE OF LIFE EXPECTANCY OF PATIENTS WITH CF FROM 16 TO 27,9 YEARS. THE ANNUAL COST OF THERAPY WAS IN 1993 1809,8, IN 1998 4266,7 AND IN 2003 23830,8 US DOLLARS. SEVERITY, AGE OF PATIENTS AND PSEUDOMONAS INFECTION WERE THE DECISIVE FACTORS IN THE TREATMENT COST